Table 1.
Demographics and baseline characteristics
| Characteristic | Roxadustat (N = 2354) |
|---|---|
| Age (years), mean (SD) | 55.5 (14.9) |
| Sex (male), n (%) | 1365 (58.0) |
| Race, n (%) | |
| Asian | 271 (11.5) |
| Black or African American | 356 (15.1) |
| White | 1581 (67.2) |
| Other | 146 (6.2) |
| BMI (kg/m2), n (%) | |
| < 25 | 977 (41.6) |
| 25 to < 30 | 718 (30.5) |
| 30 to < 35 | 369 (15.7) |
| ≥ 35 | 287 (12.2) |
| Missing | 3 |
| Type of dialysis, n (%) | |
| Hemodialysis | 2137 (90.9) |
| Peritoneal dialysis | 215 (9.1) |
| Dialysis vintage (months), mean (SD) | 33.9 (42.8) |
| Dialysis vintage, n (%) | |
| ≤ 4 months | 753 (32.0) |
| > 4 months | 1600 (68.0) |
| Missing | 1 |
| History of hypertension, n (%) | 2253 (95.7) |
| History of diabetes, n (%) | 1017 (43.2) |
| History of thromboembolism, n (%) | 100 (4.2) |
| History of CV disease, n (%) | 987 (41.9) |
| Previously treated with ESA, n (%) | |
| Naive | 562 (23.9) |
| Conversion | 1792 (76.1) |
| Previous epoetin treatment weekly dose group (IU/kg/week), n (%) | |
| Naive | 562 (25.0) |
| ≤ 150 | 1457 (64.7) |
| > 150 | 232 (10.3) |
| Missing | 103 |
| Concomitant iron therapy use (oral or IV), n (%) | 1600 (68.0) |
| Concomitant iron therapy (oral) use, n (%) | 1057 (44.9) |
| Concomitant iron therapy (IV) use, n (%) | 1088 (46.2) |
| Baseline Hb level (g/dL), mean (SD) | 9.83 (1.3) |
| Baseline ferritin level (ng/mL), median (min, max) | 497.6 (6.3, 5158.5) |
| Baseline TSAT (%), mean (SD) | 33.1 (13.1) |
| Baseline hsCRP level (mg/dL), median (min, max) | 0.44 (0.01, 28.6) |
BMI body mass index, CV cardiovascular, ESA erythropoiesis-stimulating agent, Hb hemoglobin, hsCRP high-sensitivity C-reactive protein, IU international unit, IV intravenous, SD standard deviation, TSAT transferrin saturation